Related Experiment Video
Updated: Dec 16, 2025
Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms
Published on: March 3, 2021
Combination treatments with therapeutic hypothermia for hypoxic-ischemic neuroprotection
Kelly Q Zhou1, Joanne O Davidson1, Laura Bennet1
1Department of Physiology, The University of Auckland, Auckland, New Zealand.
Insights
Therapeutic hypothermia improves outcomes for infants with hypoxic-ischemic encephalopathy. Combining hypothermia with other neuroprotective agents has shown limited success, necessitating further research into optimal treatment protocols.
Area of Science:
- Neonatal neurology
- Neuroprotection
- Perinatal medicine
Background:
- Therapeutic hypothermia effectively reduces death and disability in infants with hypoxic-ischemic encephalopathy (HIE).
- Despite treatment, many infants still experience long-term disability.
- Current hypothermia protocols are considered near-optimal, suggesting limitations in existing strategies.
Purpose of the Study:
- To review the evidence for combining therapeutic hypothermia with other neuroprotective agents.
- To explore the reasons behind the limited success of combination therapies in clinical trials.
- To emphasize the need for improved preclinical research on treatment timing and duration.
Main Methods:
- Review of preclinical and clinical studies on therapeutic hypothermia and combination neuroprotective strategies.
- Analysis of the overlapping mechanisms of action between hypothermia and other agents.
- Evaluation of clinical trial outcomes for combination treatments.
Main Results:
- Many promising neuroprotective agents share overlapping mechanisms with hypothermia (anti-excitotoxic, anti-apoptotic, anti-inflammatory).
- This overlap may explain the lack of additive benefit observed in combination treatments.
- Clinical trials of seemingly beneficial combinations have largely failed to translate.
Conclusions:
- Combining hypothermia with other neuroprotective agents has not yielded significant clinical benefits due to overlapping mechanisms.
- Future research should focus on optimizing hypothermia protocols and exploring novel therapeutic targets.
- Preclinical studies with clinically realistic protocols are crucial before initiating large-scale clinical trials.
Abstract:
Therapeutic hypothermia is now proven to reduce death or disability in term and near-term born infants with moderate to severe hypoxic-ischemic encephalopathy. Nevertheless, many infants still survive with disability, despite treatment with hypothermia. Recent preclinical and clinical studies suggest that current protocols for therapeutic hypothermia are near-optimal. The obvious strategy, in addition to improving early initiation of therapeutic hypothermia after birth, is to combine hypothermia with other neuroprotective agents. We review evidence that the mechanisms of action of many promising agents overlap with the anti-excitotoxic, anti-apoptotic, and anti-inflammatory mechanisms of hypothermia, leading to a lack of benefit from combination treatment. Moreover, even apparently beneficial combinations have failed to translate in clinical trials. These considerations highlight the need for preclinical studies to test clinically realistic protocols of timing and duration of treatment, before committing to large randomized controlled trials.
More Related Videos
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
06:43Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
Published on: November 21, 2017
